Bill
HR 2213
Overview: HR 2213 - Medical Supply Chain Resiliency ActPurpose and Intent: The Medical Supply Chain Resiliency Act aims to strengthen the resilience and security of the United Stat
Overview: HR 2213 - Medical Supply Chain Resiliency Act
Purpose and Intent: The Medical Supply Chain Resiliency Act aims to strengthen the resilience and security of the United States' medical supply chain, particularly in the wake of the COVID-19 pandemic, which exposed vulnerabilities in the system.
Key Provisions:
- Requires the Department of Health and Human Services (HHS) to develop a comprehensive national strategy for securing the medical supply chain, including the identification of critical medical products and the establishment of stockpiles and diversified sourcing.
- Provides financial incentives and tax credits to encourage the domestic production of essential medical supplies and equipment.
- Enhances the monitoring and reporting of medical supply chain disruptions, with the goal of improving early detection and response capabilities.
- Directs HHS to work with the Department of Defense and other relevant agencies to identify and address potential vulnerabilities in the medical supply chain.
Affected Parties and Impacts: The bill primarily affects the medical and pharmaceutical industries, as well as healthcare providers and consumers, by strengthening the resilience and security of the medical supply chain. The general public will also benefit from the improved availability and reliability of essential medical products during times of crisis or disruption.
Procedural and Timeline Considerations: The bill has been introduced in the House and is currently in the early stages of the legislative process. If enacted, the provisions of the bill would be implemented over a specified timeline to ensure the gradual strengthening of the medical supply chain.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
